Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Share:

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2019, Vol. 24 ›› Issue (11): 1234-1241.doi: 10.12092/j.issn.1009-2501.2019.11.004

Previous Articles     Next Articles

Study on effects of naringenin on inhibiting proliferationand invasion of ovarian cancer cells and inducing apoptosis by PI3K/AKT/NF-κB pathway

QI Bingli, HUANG Ping, YAN Ruixue, LI Qian   

  1. First Department of Gynecology, Cangzhou Central Hospital, Cangzhou 061000, Hebei, China
  • Received:2019-07-29 Revised:2019-10-30 Online:2019-11-26 Published:2019-12-02

Abstract:

AIM: To investigate the mechanism of naringenin (NAR) inhibiting the proliferation, apoptosis and invasion ability of ovarian cancer cells by PI3K/AKT/NF-κB pathway. METHODS: Ovarian cancer cells were cultured in vitro. They were divided into blank group (Control), low-dose NAR group, medium-dose NAR group and high-dose NAR group. After pretreatment with NAR, effects of NAR on proliferation, apoptosis, invasion and migration of ovarian cancer cells were detected. The expression of invasion, migration and apoptosis related proteins and PI3K/AKT/NF-κB pathway-related proteins was detected. RESULTS:The proliferation, migration and invasion of ovarian cancer cells were significantly inhibited in groups treated with NAR, while apoptosis was significantly promoted, showing dose-dependence to NAR. Compared with blank group, levels of PCNA, Bcl-2, N-cadherin, MMP-9 and MMP-2 protein were significantly decreased in the groups treated with NAR (P<0.01), while expression levels of Bax, Caspase-3, E-cadherin and PI3K protein, phosphorylation level of AKT and p65 were significantly increased (P<0.01). With increase of NAR dose, there was dose-dependence. There was no significant change in total AKT protein expression (P>0.05). CONCLUSION: NAR may inhibit proliferation and invasion ability of ovarian cancer cells by inhibiting EMT and PI3K/AKT/NF-κB pathway, and promote apoptosis of ovarian cancer cells, showing dose-dependence within a certain dose range.

Key words: ovarian cancer, naringenin, PI3K/AKT/NF-κB pathway, apoptosis

CLC Number: